Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gene Therapy for Vascular Disease

Gene Therapy for Vascular Disease Basic Science SECTION EDITOR: Bruce L. Gewertz, MD Lewis B. Schwartz, MD, and John Moawad, MD, Chicago, Illinois Atherosclerosis is a degenerative process characterized by endothelial cell dysfunction, inflam- matory cell adhesion and infiltration, and the accumulation of cellular and matrix elements leading to the formation of fibrocellular plaques. In the end stages, advanced occlusive plaques limit blood flow and oxygen delivery resulting in the well-known ischemic syndromes of the coronary, skeletal muscle, mesenteric, and cerebrovascular circulation. Moreover, sudden criti- cal ischemic events may be precipitated by plaque disturbance, rupture, hemorrhage, and/or thrombosis. Traditional pharmacologic approaches have been effective in reducing serum cho- lesterol and controlling thrombosis but, in the main, have had little impact on the treatment of advanced lesions. The purpose of this review is to examine the current status of gene therapy for vascular proliferation, aberrant endothelial function, thrombosis, peripheral ischemia, and modification of the blood/biomaterial interface. (Ann Vasc Surg 1997,11:189-199.) gene, causing rats to exhibit high levels of serum HISTORY OF GENE THERAPY insulin and hypoglycemia. The feasibility of gene The notion of gene therapy began with the redis- transfer into vascular tissue was first demonstrated covery of Gregor Mendel’s nineteenth century ex- in 1989 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Vascular Surgery Springer Journals

Gene Therapy for Vascular Disease

Loading next page...
 
/lp/springer-journals/gene-therapy-for-vascular-disease-KUp9x68DUt

References (103)

Publisher
Springer Journals
Copyright
Copyright © Inc. by 1997 by Annals of Vascular Surgery
Subject
Medicine & Public Health; Abdominal Surgery
ISSN
0890-5096
eISSN
1615-5947
DOI
10.1007/s100169900034
pmid
9181778
Publisher site
See Article on Publisher Site

Abstract

Basic Science SECTION EDITOR: Bruce L. Gewertz, MD Lewis B. Schwartz, MD, and John Moawad, MD, Chicago, Illinois Atherosclerosis is a degenerative process characterized by endothelial cell dysfunction, inflam- matory cell adhesion and infiltration, and the accumulation of cellular and matrix elements leading to the formation of fibrocellular plaques. In the end stages, advanced occlusive plaques limit blood flow and oxygen delivery resulting in the well-known ischemic syndromes of the coronary, skeletal muscle, mesenteric, and cerebrovascular circulation. Moreover, sudden criti- cal ischemic events may be precipitated by plaque disturbance, rupture, hemorrhage, and/or thrombosis. Traditional pharmacologic approaches have been effective in reducing serum cho- lesterol and controlling thrombosis but, in the main, have had little impact on the treatment of advanced lesions. The purpose of this review is to examine the current status of gene therapy for vascular proliferation, aberrant endothelial function, thrombosis, peripheral ischemia, and modification of the blood/biomaterial interface. (Ann Vasc Surg 1997,11:189-199.) gene, causing rats to exhibit high levels of serum HISTORY OF GENE THERAPY insulin and hypoglycemia. The feasibility of gene The notion of gene therapy began with the redis- transfer into vascular tissue was first demonstrated covery of Gregor Mendel’s nineteenth century ex- in 1989

Journal

Annals of Vascular SurgerySpringer Journals

Published: Mar 1, 1997

There are no references for this article.